Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1242-1248

  Prebet, Thomas ^a   Sun, Zhuoxin ^b   Figueroa, Maria E ^c   Ketterling, Rhett ^h   Melnick, Ari ^c   Greenberg, Peter L ⁱ   Herman, James ^a   Juckett, Mark ^j   Wang, Eunice S ^g   Smith, Mitchell R ^k   Malick, Lisa ^a   Paietta, Elisabeth ^f   Czader, Magdalena ^l   Litzow, Mark ^h   Gabrilove, Janice ^d   Erba, Harry P ^m   Gore, Steven D ^a   Tallman, Martin S ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; ENTINOSTAT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BENZAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL PROTOCOL; CYTOGENETICS; DEMETHYLATION; DISEASE COURSE; DNA METHYLATION; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; THROMBOCYTOPENIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BENZAMIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904066247     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3102     Document Type: Article

References (29)

1. Stone RM: How I treat patients with myelodysplastic syndromes. Blood 113:6296-6303, 2009
2. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003 (Pubitemid 37448928)
3. Figueroa ME, Lugthart S, Li Y, et al: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13-27, 2010
4. Jiang Y, Dunbar A, Gondek LP, et al: Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315-1325, 2009
5. Shen L, Kantarjian H, Guo Y, et al: DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605-613, 2009
6. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
7. Linggi BE, Brandt SJ, Sun ZW, et al: Translating the histone code into leukemia. J Cell Biochem 96:938-950, 2005 (Pubitemid 41688720)
8. Cameron EE, Bachman KE, Myohanen S, et al: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107, 1999 (Pubitemid 29036293)
9. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002 (Pubitemid 34525728)
10. Silverman LR, McKenzie DR, Peterson BL, et al: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-3903, 2006 (Pubitemid 46630737)
11. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
12. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
13. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
14. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569, 2010
15. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: Newer agents and the role of combination approaches. Cancer Control 2008:40-49, 2008 (suppl 15)
16. Gore SD: Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol:S30-S35, 2005 (suppl 1)
17. Gore SD, Baylin S, Sugar E, et al: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369, 2006
18. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al: Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 2006
19. Soriano AO, Yang H, Faderl S, et al: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308, 2007 (Pubitemid 47523148)
20. Gojo I, Jiemjit A, Trepel JB, et al: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:2781-2790, 2007 (Pubitemid 46482071)
21. Fandy TE, Herman JG, Kerns P, et al: Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764-2773, 2009
22. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
23. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
24. Figueroa ME, Skrabanek L, Li Y, et al: MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448-3458, 2009
25. Lyons RM, Cosgriff TM, Modi SS, et al: Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850-1856, 2009
26. Pollyea DA, Kohrt HE, Gallegos L, et al: Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 26:893-901, 2012
27. Silverman LR, Verma A, Odchimar-Reissig R, et al: A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 26:15S, 2008 (suppl; abstr 7000)
28. Garcia-Manero G, Estey E, Jabbour E, et al: Final report of a phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinical trials because poor performance and presence of other comorbidities. 53rd ASH Annual Meeting and Exposition, San Diego, CA, December 10-13, 2011 (abstr)
29. Reddy PN, Sargin B, Choudhary C, et al: SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood 120:1691-1702, 2012